Last updated: March 1, 2026
What Is the Drug Corresponding to NDC 00781-5625?
NDC 00781-5625 refers to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor approved for treating rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune diseases. The drug is marketed by Pfizer.
Market Overview
Therapeutic Usage and Population
- Indications: Rheumatoid arthritis, psoriatic arthritis, UC, and others.
- Global patient population: Estimated at over 4 million, with approximately 2 million in the U.S.
- Market penetration: Rising due to expanding indications and preference for oral agents over biologics.
Competitive Landscape
| Drug |
Class |
Approved Indications |
Estimated U.S. Sales (2022) |
Market Share (2022) |
| Xeljanz (tofacitinib) |
JAK inhibitor |
RA, PsA, UC |
$2.1 billion |
25% |
| Humira (adalimumab) |
Anti-TNF biologic |
RA, UC, PsA |
$20 billion (overall) |
15% |
| Rinvoq (upadacitinib) |
JAK inhibitor |
RA, UC |
$2.8 billion |
10% |
| Eliquis (apixaban) |
Anticoagulant |
Blood clots, Afib |
$8.6 billion |
4% |
Xeljanz ranks as the leading oral JAK inhibitor but faces competition from Rinvoq, another Pfizer product, and biologic therapies.
Market Drivers
- Adoption of oral JAK inhibitors over biologics.
- Expanding approval for new indications, such as atopic dermatitis.
- Increased diagnosis rates for autoimmune diseases.
- Preference shifts toward self-administered therapies.
Key Market Risks
- Competitive pressure from other JAK inhibitors and biologics.
- Regulatory scrutiny over safety concerns, including thromboembolic risks.
- Pricing pressures due to healthcare cost containment.
Price Analysis and Projections
Current Pricing
- Unit cost (U.S.): Approximately $1,800 per 30-tablet supply.
- Average annual treatment cost per patient: Around $21,600.
- Price varies by payer and patient assistance programs.
Historical Price Trends
| Year |
Average Wholesale Price (AWP) per 30 tablets |
Notes |
| 2020 |
$1,750 |
Baseline |
| 2022 |
$1,800 |
Slight increase observed |
| 2023 |
$1,820 |
Ongoing inflation |
Prices have increased modestly over the recent years, driven by inflation and manufacturing costs.
Future Price Projections (2024-2028)
- Assumption: Moderate annual increase of 2-3% due to inflation and market dynamics.
- Projected unit price (2028): Approximately $2,100 per 30 tablets.
- Annual treatment cost projection: $25,200 per patient.
Market Revenue Projections
- 2023: ~$2.6 billion in U.S. sales.
- 2028 estimate: ~$3.2 billion, assuming continued market penetration and stability in pricing.
Impact of Biosimilars and Competition
- Patent expiration in key markets expected around 2025.
- Entry of biosimilars could reduce prices by 15-30% over five years.
- Pfizer’s aggressive lifecycle management and new indications may mitigate revenue erosion.
Regulatory and Policy Factors Affecting Price
- FDA safety updates could influence prescribing patterns.
- Value-based pricing models gaining traction.
- Price negotiations and formularies increasingly impacting reimbursement.
- Medicare and Medicaid pricing policies may reduce net prices.
Conclusions
- Current U.S. patent exclusivity supports stable pricing until roughly 2025.
- Prices are projected to rise slowly; marginal reductions may occur with biosimilar competition.
- Total market revenue is expected to grow, driven by increased utilization and expanding indications.
- Competitive risks from biosimilars and safety concerns will influence long-term pricing strategies.
Key Takeaways
- NDC 00781-5625 corresponds to Xeljanz, a key player in the JAK inhibitor space.
- The drug’s U.S. sales hit approximately $2.1 billion in 2022, with a steady incremental price increase.
- Market growth is driven by expanded indications and oral administration preference, but threatened by biosimilars.
- Prices are expected to increase gradually, reaching around $2,100 per 30 tablets by 2028.
- Revenue projections remain optimistic but are contingent on regulatory decisions, safety perceptions, and biosimilar entry.
FAQs
1. When will biosimilars for Xeljanz enter the market?
Patent protection expires around 2025 in the U.S., with biosimilar contenders likely to launch shortly thereafter.
2. How might safety concerns influence the drug’s market?
Safety issues such as thromboembolic risks have led to safety communications; increased risk perception could reduce prescriber confidence and market share.
3. Are there significant regional price differences for Xeljanz?
Yes, prices vary by country, regulatory environment, and healthcare system, often being lower outside the U.S.
4. What impact will new indications have on revenue?
Expanded indications tend to increase patient population size and sales volume, potentially offsetting price pressures.
5. How does Xeljanz compare to other JAK inhibitors?
It is generally priced slightly lower than Rinvoq but competes well on efficacy and convenience for patients.
References
[1] IQVIA. (2022). National Prescription Audit.
[2] Pfizer. (2023). Xeljanz Prescribing Information.
[3] EvaluatePharma. (2023). World Preview 2023, Outlook to 2028.
[4] FDA. (2021). Safety Communication on JAK Inhibitors.
[5] U.S. Department of Health and Human Services. (2022). Pricing and reimbursement policies.
